Screening of Investigational Therapeutics to Treat, Modify or Prevent Epilepsy for the NINDS Epilepsy Therapy Screening Program (ETSP)
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $50,000,000 to $100,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health estimates a July 1, 2026 solicitation release for a follow-on contract to screen, test, and identify investigational therapeutics that can be developed into new treatments for epilepsy under the NINDS Epilepsy Therapy Screening Program (ETSP), with an estimated award date of January 1, 2027. The work covers in vivo and in vitro testing, including human-based new approach methods (NAMs), performed blinded and confidentially by the contract laboratory at no cost to qualified, enrolled ETSP participant projects from academia and research organizations. The follow-on succeeds active NINDS contract 75N95022C00007, is coded under NAICS 541715, and is listed as having no set-aside.
The estimated award value range is $50 million to $100 million. The forecast does not identify a place of performance or a service timeline. Brian Klein, Program Director, Division of Translational Research at NINDS (brian.klein@nih.gov, +1 301-496-0981), and Rieka Plugge, Contracting Officer at NIH (rieka.plugge@nih.gov, +1 301-827-7515), are the listed points of contact.
Forecast text
Epilepsy is a chronic disease impacting 3 million Americans across the lifespan including half a million children. The purpose of this acquisition is to award a follow-on contract for the screening, testing, and identification of potential candidate therapies that can be further developed as new therapies that target mechanisms associated with the epilepsies, currently being performed under active NINDS contract 75N95022C00007, "Screening of Investigational Compounds to Treat, Modify or Prevent Epilepsy for the NINDS Epilepsy Therapy Screening Program (ETSP)". The NINDS ETSP, known as the Anticonvulsant Screening Program (ASP) until 2015, was established in 1975 to address a critical need for new anti-seizure medications. Since its inception, the program has been supported through a contract to the University of Utah, which NINDS initially awarded after open competitions in 1974, 1980, and 1984, renewed thereafter on a sole-source basis until 2016 when the contract was awarded following full and open competitions. The screening process involves researchers from academia and research organizations ("ETSP participants") submitting investigational therapeutics to the ETSP for evaluation in a series of in vivo and in vitro tests including human based new approach methods (NAMs). These tests are performed blinded by the contract laboratory and on a confidential basis through a written agreement between the NINDS and the ETSP participant at no cost to qualified and enrolled ETSP participant projects. The NINDS ETSP program reports test results to participants and provides advice on future steps for promising compounds, while protecting confidentiality and intellectual property. Over 32,000 investigational therapeutics have been successfully screened to date, and the ETSP has contributed to bringing 11 clinically approved therapies to market since 1990.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast